Dar Al Dawa Development and Investment (AMM:DADI) YoY EBITDA Growth: -4.44% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMM:DADI Dar Al Dawa Development and Investment AMM:DADI
78 GF Score
Price JOD1.23
GF Value JOD1.04
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Dar Al Dawa Development and Investment YoY EBITDA Growth?

Dar Al Dawa Development and Investment AMM:DADI 78 YoY EBITDA Growth is -4.44% as of Jun. 2026. GuruFocus rates AMM:DADI with a GF Score™ of 78/100 and a GF Value™ of JOD1.04 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Dar Al Dawa Development and Investment's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -4.44%.

Dar Al Dawa Development and Investment's EBITDA per Share for the three months ended in Jun. 2026 was JOD0.09.

Dar Al Dawa Development and Investment YoY EBITDA Growth Related Terms

Dar Al Dawa Development and Investment YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Dar Al Dawa Development and Investment's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dar Al Dawa Development and Investment YoY EBITDA Growth Chart

Dar Al Dawa Development and Investment Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.09 -32.49 98.50 29.17 8.80

Dar Al Dawa Development and Investment Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.35 -38.71 39.78 -23.61 -4.44
AMM:DADI
78GF Score
Dar Al Dawa Development and Investment AMM:DADI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dar Al Dawa Development and Investment YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Dar Al Dawa Development and Investment's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.371-0.341)/ | 0.341 |
=8.80 %

Dar Al Dawa Development and Investment's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.086-0.09)/ | 0.09 |
=-4.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -4.44% mean?
Dar Al Dawa Development and Investment (AMM:DADI) has a YoY EBITDA Growth of -4.44% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Dar Al Dawa Development and Investment and its competitors.
Is Dar Al Dawa Development and Investment's YoY EBITDA Growth too high?
Dar Al Dawa Development and Investment's current YoY EBITDA Growth is -4.44%. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's YoY EBITDA Growth compare to ZTS and UTHR?
Dar Al Dawa Development and Investment's YoY EBITDA Growth of -4.44% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Dar Al Dawa Development and Investment and its competitors. Dar Al Dawa Development and Investment's current YoY EBITDA Growth is -4.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.04, compared to a current price of JOD1.23 — trading 18.3% above its estimated fair value. The current YoY EBITDA Growth is -4.44%. Dar Al Dawa Development and Investment's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current YoY EBITDA Growth is -4.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?

Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued. The current stock price of JOD1.23 is trading 18.3% above its estimated GF Value™ of JOD1.04. GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.

Key valuation signals for AMM:DADI:

  • YoY EBITDA Growth: -4.44%
  • GF Value™: JOD1.04 vs. price of JOD1.23 (18.3% above fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dar Al Dawa Development and Investment Business Description

Address Naour, P.O. Box 9364, Amman, JOR, 11191
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
78GF Score

Get the complete analysis for AMM:DADI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD1.23
Price
JOD1.04
GF Value